Sichuan Biokin Pharmaceutical Co., Ltd.

Sichuan Biokin Pharmaceutical Co., Ltd. saw a significant rise in its stock on June 10, 2026, despite broader market declines. The company has faced ongoing financial challenges, reporting substantial losses and declining sales over the past year, while showing notable growth over the past three years.

Sichuan Biokin Pharmaceutical Co., Ltd. saw its stock decline significantly, contrasting with the broader market's performance. The company reported a substantial drop in net sales and a notable net profit loss, indicating ongoing challenges in the pharmaceuticals and biotechnology sector. Year-to-date, the stock has experienced a steep decline.

Sichuan Biokin Pharmaceutical Co., Ltd. faced notable stock volatility on June 1, 2026, with a significant decline. Over the past week and month, the stock has dropped considerably, reflecting ongoing financial challenges, including a sharp decrease in net sales and a substantial net loss for the last nine months.

Sichuan Biokin Pharmaceutical Co., Ltd. saw a notable stock increase today, contrasting with a decline in the broader market. However, the company has faced significant challenges, including a sharp drop in net sales and profit over the past year, reflecting ongoing financial pressures in the pharmaceutical sector.

Sichuan Biokin Pharmaceutical Co., Ltd. faced a notable decline in stock performance, with a significant drop today and a continued downward trend over the past month. Financial results reveal a sharp decrease in net sales and profit, indicating ongoing challenges for the company amid fluctuating market conditions.

Sichuan Biokin Pharmaceutical Co., Ltd. faced a significant stock decline today, contrasting with the positive performance of the China Shanghai Composite. The company reported a substantial drop in net sales and a notable net profit loss, indicating ongoing financial challenges despite previous gains over three years.

Sichuan Biokin Pharmaceutical Co., Ltd. saw a notable increase in its stock price on March 27, 2026, reaching an intraday high. The company has outperformed the China Shanghai Composite index recently, despite facing challenges with declining net sales and consecutive quarterly losses, maintaining a significant market capitalization.

Sichuan Biokin Pharmaceutical Co., Ltd. faced a decline in stock value, reflecting ongoing financial challenges. The company reported significant negative net sales growth and a substantial drop in net profit over the past nine months. Liquidity concerns are evident, with low operating cash flow and a market capitalization of CNY 29,530 million.

Sichuan Biokin Pharmaceutical Co., Ltd. faced a significant stock decline today, reflecting ongoing market volatility. The company has reported negative results for four consecutive quarters, with a substantial drop in net sales and a notable loss in net profit. Its market capitalization stands at CNY 29,530 million.

Sichuan Biokin Pharmaceutical Co., Ltd. saw a significant rise in its stock on March 16, 2026, reaching an intraday high. The company has shown resilience with a recent weekly increase, although its year-to-date performance remains negative. It maintains a strong annual growth rate despite facing recent financial challenges.

Sichuan Biokin Pharmaceutical Co., Ltd. faced a significant stock decline today, reflecting ongoing market challenges. Over the past month, the stock has dropped notably, with year-to-date losses also evident. Recent quarterly results showed substantial declines in net sales and profit, raising concerns about the company's financial health.

Sichuan Biokin Pharmaceutical Co., Ltd. saw a significant stock decline today, contrasting with a slight increase in the China Shanghai Composite. Despite a recent weekly gain, the company faces challenges with a substantial drop in net sales and a notable net profit loss, impacting its market position in the pharmaceuticals sector.

Sichuan Biokin Pharmaceutical Co., Ltd. saw a notable stock price increase on March 10, 2026, contrasting with the modest rise of the China Shanghai Composite. Despite recent volatility, the company has achieved substantial long-term growth, significantly outpacing the broader market over the past three years. Its market capitalization is CNY 29,530 million.

Sichuan Biokin Pharmaceutical Co., Ltd. saw a significant rise in its stock today, contrasting with a decline in the broader market. Despite this uptick, the company has struggled financially, reporting substantial decreases in net sales and profits over the past nine months, alongside a notable year-to-date decline.

Sichuan Biokin Pharmaceutical Co., Ltd. saw a significant stock decline today, contrasting with the broader market's performance. Over the past week and month, the stock has faced notable decreases, and year-to-date figures reflect ongoing challenges. Financial metrics indicate negative growth and a substantial drop in net profit.

Sichuan Biokin Pharmaceutical Co., Ltd. saw a significant stock decline today, contrasting with the broader market's performance. The company has struggled over the past week and year-to-date, facing negative results in recent quarters, including drops in net sales and profit, amid challenging financial metrics.

Sichuan Biokin Pharmaceutical Co., Ltd. faced a significant stock decline on February 25, 2026, marking a challenging trading session. The company has experienced a year-to-date drop, with net sales and profits also declining sharply. Despite past growth, it now navigates a difficult market environment.